HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D’Errico, C. C. Search for Related Content PubMed PubMed Citation Articles by D’Errico, C. C.

Ann Thorac Surg 1998;65:S52-S55
© 1998 The Society of Thoracic Surgeons

Pharmacoeconomics Analysis in a Pediatric Population

^a Department of Pediatric Anesthesiology, Mott Children’s Hospital, University of Michigan Medical Center, Ann Arbor, Michigan, USA

Address reprint requests to Dr D’Errico, Pediatric Anesthesiology, Mott Children’s Hospital, University of Michigan Medical Center, 1500 E Medical Center Dr, Rm F-3900, Ann Arbor, MI 48109-0211

Presented at Risk Assessment of Major Perioperative Issues in Pediatric Cardiac Surgery, Washington, DC, May 7, 1997.

Background. Pharmacoeconomics is becoming increasingly important in the health-care environment, but pharmacoeconomic studies are fraught with problems. Pharmacoeconomics can be applied to analysis of the benefits of pharmacologic hemostasis.

Methods. This article reviews the available methods of pharmacoeconomic analysis and their inherent methodologic concerns. It reviews pharmacoeconomic studies of pharmacologic hemostasis, with particular focus on the Pediatric Reoperative Open Heart Surgery Study. In this study, patients were randomized to receive either high-dose aprotinin, low-dose aprotinin, or placebo. Results were analyzed from the viewpoint of cost-benefit, cost-effectiveness calculated with use of a roll-back decision tree, and cost-effective ratios.

Results. Cost-benefit analysis showed low-dose aprotinin to have a greater cost-benefit than high-dose aprotinin, cost-effectiveness analysis and analysis of cost-effective ratios showed high-dose aprotinin to be more cost-effective than low-dose aprotinin, and all analyses showed aprotinin to be preferable to placebo.

Conclusions. Aprotinin in pediatric repeat open heart operations not only has a cost-benefit but is cost-effective as well.

This article has been cited by other articles:

				E. B. Mossad, S. Machado, and J. Apostolakis Bleeding following deep hypothermia and circulatory arrest in children. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 34 - 46. [Abstract] [PDF]

				I. Shen, C. Giacomuzzi, and R. M. Ungerleider Current strategies for optimizing the use of cardiopulmonary bypass in neonates and infants Ann. Thorac. Surg., February 1, 2003; 75(2): S729 - 734. [Abstract] [Full Text] [PDF]

				L. A. Gramlich and S. D. Barnes Aprotinin Use in Pediatric Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2001; 5(1): 117 - 121. [Abstract] [PDF]